Navigation Links
Alfacell Corporation to Present at UBS Global Life Sciences Conference
Date:9/19/2007

SOMERSET, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8:30 a.m. EDT on Sept. 26, 2007, at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City.

The live Webcast of the presentation will be available on Alfacell's Web site at http://www.alfacell.com. A replay of the Webcast will be available online for 30 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
3. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
4. Researchers Identify Intracellular Pathway of Alfacells Onconase
5. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
6. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
7. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
8. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
9. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
10. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
11. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... (PRWEB) , ... August 07, ... ... Officer, today announced the appointment of Richard A. Stark to assume the role of Sanarus Technologies President, ... his 20+ years of strategic development, marketing and sales experience in medical device toward ...
(Date:8/3/2018)... ... August 03, 2018 , ... Flexefits, a pioneer in direct -pay, direct ... its allowing participants in Direct Primary Care arrangements to keep HSA eligibility and permit ... per individual and $300 per family per month.) , “We are very pleased to ...
(Date:8/3/2018)... (PRWEB) , ... August 03, 2018 , ... In order ... Firm are urging families to be mindful of the significant risks of injury that ... summer without a spin on the Ferris wheel or a thrilling ride on a ...
Breaking Medicine Technology:
(Date:8/9/2018)... ... August 09, 2018 , ... ... is a new verification process that substance abuse providers must pass in order ... we can reach more people to help.” , Helping people is what ...
(Date:8/9/2018)... ... August 09, 2018 , ... ... Kathy Coover and the company’s independent distributors, customers, and employees, the newly established ... of fundraising, exceeding the $2 million goal. 100 percent of the donations will ...
(Date:8/7/2018)... ... August 07, 2018 , ... Today Springfield Creamery ... Foods. These rich, cream-on-top-style yogurts are made with milk from grass-fed cows who ... in omega-3 fatty acids. Nancy’s sources the milk from organic family-owned farms, all ...
(Date:8/3/2018)... ... August 03, 2018 , ... On August 2, 2018 the ... Mark Sadaka of Sadaka Associates, LLC has been litigating Zostavax injuries ... the Judicial Panel on Multidistrict Litigation for the thousands of people injured by Zostavax, ...
(Date:8/2/2018)... ... , ... Dr. Srini Pillay , best-selling author of TINKER DABBLE ... care less, demonstrating a “whatever” attitude toward life, people, and situations around them. , ... overlooked reason relates to being overworked. Called self-regulation depletion (SRD), this condition occurs when ...
Breaking Medicine News(10 mins):